Population genetic testing to detect inherited cancer risk
Official title: Population Based Germline Testing for Early Detection and Prevention of Cancer
Run by Queen Mary University of London · NCT07498829 · Data updated 2026-11-12
This project will see if offering genetic testing to adults with female reproductive organs can find inherited changes that raise risk of breast, ovarian, bowel, and womb cancers so they can get earlier screening or preventive care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 6000 (estimated) |
| Sponsor | Queen Mary University of London Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | December 18, 2025 |
| Main results expected | December 2029 |
| Study ends | December 2040 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT07498829 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with female reproductive organs (including women, trans men, and non-binary people) who have not previously had genetic testing for the listed genes and who can provide informed consent.
✕Probably not a fit
People who have already had genetic testing for the specified genes, who have a first- or second-degree relative with a known pathogenic variant in those genes, or who cannot provide informed consent are unlikely to benefit from joining.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This programme offers panel genetic testing for key cancer susceptibility genes (including BRCA1/2, PALB2, RAD51C/D, BRIP1, and several mismatch repair genes) to adults with female reproductive organs regardless of family history. Participants give consent, provide a sample, and receive personalised breast and ovarian cancer risk information and guidance on NHS screening or prevention options. People with prior testing for the listed genes or a known familial pathogenic variant are excluded. The project will test whether population-based germline testing is feasible and effective at identifying carriers and linking them to prevention pathways.
Why it matters
Potential benefit: If successful, this could identify people with high inherited cancer risk who can access earlier screening or preventive treatments, potentially reducing advanced cancers and deaths.
How similar studies have gone: Prior targeted programmes and pilot population-screening projects have shown broader genetic screening can identify many carriers, but large-scale routine population testing is still being tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women, trans men, and non-binary people with female reproductive organs * ≥18 years at consent Exclusion Criteria: * Individuals who have previously undergone genetic testing for one or more of the following CSGs: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6 * One or more first- or second-degree relative with a PV in any of above CSGs * Inability to provide informed consent
Where it's running
-
Wolfson Institute of Population Health, Queen Mary University of London
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Ranjit Manchanda, PhD — Wolfson Institute of Population Health, Queen Mary University of London
- Study coordinator: Ranjit Manchanda, PhD
- Email: r.manchanda@qmul.ac.uk
- Phone: +44 8008620236
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Genetic assessment of breast cancer risk for women in the DORA programme
This study tests whether a detailed clinical and genetic review can better classify breast cancer risk for women previously identified as moderately increased or high risk.
-
AI (Mirai)-guided supplemental MRI to find breast cancer in women at high Mirai risk
This will test whether adding a screening breast MRI finds more cancers in women whose mammograms are flagged as high risk by the Mirai AI model.
-
Understanding how genes affect breast cancer risk
This study is trying to see how genes affect the risk of breast cancer by collecting health surveys and saliva samples from people aged 18 and older in the US.
-
Analyzing cancer genetics for better prevention and treatment
This study is trying to find genetic clues in cancer patients' samples to improve prevention and treatment options for cancer.
-
Study on cancer risks linked to CTNNA1 gene mutations
This study is trying to find out if certain gene changes in the CTNNA1 gene increase the risk of cancers like gastric and breast cancer for people who have these changes in their family.
-
Research on health inequality and genetic disparity in cardiovascular diseases
This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.